Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search


A genetics testing company founded in 2013, based in San Francisco.

Color Genomics provides a physician-ordered test for hereditary cancer risk.The Color test analyses 2-60 genes, depending on the chosen test, looking at genes associated with cancer and cardiovascular disease in a saliva sample. Mary-Claire King who discovered BRCA1 is an advisor for Color2. Patients can sign up for the test on the website, which will be delivered once approved by the primary physician or a Color network physician. The cost of up to $349 can be paid by the individual or alternatively Color works with insurance companies.

A criticism for their test is that outside of BRCA1 and BRCA2, which account for 5-10% of all breast cancers, not enough is known about the tested genes and how environment and lifestyle come into play for doctors to act on test results. Color has board-certified genetic councilors on staff to interpret results and explain them to users.

Color has partnered with companies including Slack, Medium, Stripe, VISA and Levis to offer subsidized Color tests a benefit for employees. The ATHENA Breast Health Network at University of California, San Francisco uses Color tests to screen women with a view to optimizing or reducing mammography depending on personal risk.


November 9, 2021
Color raises a $100,000,000 series E round from Emerson Collective, General Catalyst, Kindred Ventures, T. Rowe Price and Viking Global Investors.
January 4, 2021
Color raises $167 million funding at $1.5 billion valuation to expand 'last mile' of US health infrastructure. This latest investment into Color was led by General Catalyst, and by funds invested by T. Rowe Price, along with participation from Viking Global investors as well as others.
January 4, 2021
Color raises a $167,000,000 series D round from General Catalyst, T. Rowe Price and Viking Global Investors.
January 2021
Color raises a $1,500,000,000 series D round from General Catalyst, T. Rowe Price and Viking Global Investors.
January 2020
Color raises a $75,000,000 series D round from T. Rowe Price and Viking Global Investors.
August 2017
Color raises a $81,201,261 series C round from Charles River Ventures, Emerson Collective, General Catalyst, LeFrak Ventures, LionTree Partners and Pegasus Tech Ventures.
September 2016
Color raises a $45,000,000 series B round from Brainchild Holdings, Caffeinated Capital, Emerson Collective, Formation 8, General Catalyst, Khosla Ventures, LeFrak Ventures, SV Angel and Shasta Ventures.
April 2015
Color raises a $15,000,000 series A round from Katie Stanton, Khosla Ventures, Laurene Powell Jobs, LeFrak Ventures, Lee Linden, Mariam Naficy, Max Levchin, Padmasree Warrior, Raymond Tonsing and Ruchi Sanghvi.
Color launched in 2015 with a focus on gene testing and precision genomics.

Funding Rounds


Further Resources


Case study on Color



April 28, 2020


Janice Bitters
October 13, 2021
Crunchbase News
The pandemic set in motion a new trajectory for many health tech startups, particularly those nimble enough to respond to a world crisis that confused and broke traditional public health care systems.
Jonathan Shieber
October 10, 2019
Color Genomics, the genetics testing company, is partnering with Alphabet's health technology focused subsidiary, Verily Life Sciences, to provide information from its genetic tests to the company's Baseline Health Study participants. The emphasis from both companies is on providing "actionable" results. While genetic testing services have caught the public's imagination for their ability to provide [...]


Golden logo
By using this site, you agree to our Terms & Conditions.